Therefore, our data imply that targeting tumoral ASAP2 is potentially a more precise therapeutic strategy for inhibiting c-MET signaling in HCC with a minimal impact on c-MET activation in normal cells. The gene discussed is MET; the disease is hepatocellular carcinoma.